VIVOZON PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,840 KRW | -0.35% |
|
-2.07% | -5.33% |
| Sales 2022 | 59.07B 43.24M 3.61B | Sales 2023 | 71.32B 52.2M 4.35B | Capitalization | 145B 106M 8.83B |
|---|---|---|---|---|---|
| Net income 2022 | -38.46B -28.15M -2.35B | Net income 2023 | -3.36B -2.46M -205M | EV / Sales 2022 | 3.07 x |
| Net Debt 2022 | 32.47B 23.77M 1.98B | Net Debt 2023 | 23.89B 17.49M 1.46B | EV / Sales 2023 | 2.36 x |
| P/E ratio 2022 |
-3.6
x | P/E ratio 2023 |
-42.6
x | Employees | 238 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 61.95% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.35% | ||
| 1 week | -2.07% | ||
| Current month | -17.32% | ||
| 1 month | -17.32% | ||
| 3 months | -2.41% | ||
| 6 months | -16.22% | ||
| Current year | -5.33% |
1 week
2 800.00
2 995.00
1 month
2 800.003 710.00
Current year
2 800.003 990.00
1 year
2 395.004 635.00
3 years
2 075.009 400.00
5 years
2 075.0017 625.00
10 years
2 075.0017 625.00
| Managers | Title | Age | Since |
|---|---|---|---|
Dong-Hoon Oh
CEO | Chief Executive Officer | 52 | - |
Jae-Gwan Han
CEO | Chief Executive Officer | 58 | 01/13/01 |
Seung-Rak Hong
DFI | Director of Finance/CFO | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jae-Gwan Han
CEO | Chief Executive Officer | 58 | 01/13/01 |
Yoon-Chul Lee
BRD | Director/Board Member | 53 | 20/20/20 |
Dong-Hoon Oh
CEO | Chief Executive Officer | 52 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/24/02 | 2,855 | +0.53% | 102,209 |
| 30/24/30 | 2,840 | -0.35% | 69,249 |
| 29/24/29 | 2,850 | -.--% | 72,953 |
| 26/24/26 | 2,850 | -0.87% | 81,250 |
| 25/24/25 | 2,875 | -0.86% | 99,148 |
End-of-day quote Korea S.E., April 30, 2024
More quotes
Vivozon Pharmaceutical Co Ltd , formerly Vivozon Healthcare Inc, is a Korea-based company mainly engaged in the manufacture and sale of finished pharmaceutical products. The Company operates its business through three segments. The Pharmaceutical Business segment is engaged in the manufacture and sale of finished medicines such as external skin preparations, antipyretic analgesic, anti-inflammatory drugs and antidiabetic drugs. The Optical Business segment is engaged in the manufacture and sale of finished products and lighting module sets such as general lighting and automotive lighting using light emitting diode (LED) light sources. The Cosmetics Business segment is engaged in the manufacture and sale of cosmetics and cosmetic ingredients.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -5.33% | 96.88M | |
| +30.22% | 699B | |
| +25.07% | 571B | |
| -4.41% | 364B | |
| +18.39% | 326B | |
| +3.48% | 286B | |
| +14.68% | 236B | |
| +4.71% | 198B | |
| -12.43% | 194B | |
| -3.43% | 154B |
- Stock Market
- Equities
- A082800 Stock
